Bristol-Myers Squibb Co. (BMS), of New York, and AstraZeneca plc, of London, reported that AstraZeneca made an initial payment of about $3.2 billion to Amylin Pharmaceuticals, now a wholly owned BMS subsidiary, in connection with an expanded diabetes alliance
Bristol-Myers Squibb Co. (BMS), of New York, reported the successful completion of its tender offer for all outstanding shares of Amylin Pharmaceuticals Inc., of San Diego, at $31 per share
Eli Lilly and Co., of Indianapolis, and Bristol-Myers Squibb Co., of New York, said Erbitux (cetuximab) in combination with chemotherapy regimen Folfiri (irinotecan, 5-fluorouracil, leucovorin) is the first biologic treatment regimen in nearly a decade to receive FDA approval for newly diagnosed metastatic colorectal cancer
Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, said the FDA issued a complete response letter (CRL) on the new drug application for Eliquis (apixaban) for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation
Bristol-Myers Squibb Co., of Princeton, N.J., said it helped form the International Immuno-Oncology Network, a global collaboration between industry and academia aimed at furthering the scientific understanding of immune-oncology, which focuses on the potential of harnessing the intelligence of the body's own immune system to fight cancer
Bristol-Myers Squibb Co., of New York, said it formed a relationship with Duke Translational Medicine Institute (DTMI), which will build on a decade of collaboration in cardiology, endocrinology and oncology and extend into other therapeutic areas at all stages of development
Bristol-Myers Squibb Co. (BMS), of New York, and AstraZeneca plc, of London, reported that AstraZeneca made an initial payment of about $3.2 billion to Amylin Pharmaceuticals, now a wholly owned BMS subsidiary, in connection with an expanded diabetes alliance